Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder

Journal of Psychiatric Research

Volumn 45, Issue 1, 2011, Pages 54-59

  Reynolds, Lindsay M ^a   Reynolds, Gavin P ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bipolar disorder; Frozen brain sections; Major depressive disorder; N acetylaspartate; N acetylaspartylglutamate; Schizophrenia

Indexed keywords

N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; AUTOPSY; BIPOLAR DISORDER; BRAIN LEVEL; BRAIN TISSUE; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR DEPRESSION; MALE; NUCLEUS ACCUMBENS; PARAHIPPOCAMPAL GYRUS; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA;

ADULT; ASPARTIC ACID; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; DIPEPTIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 78650936471     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.05.001     Document Type: Article

References (51)

1. Battistuta J., Bjartmar C., Trapp B.D. Postmortem degradation of N-acetyl aspartate and N-acetyl aspartylglutamate: an HPLC analysis of different rat CNS regions. Neurochemical Research 2001 Jun, 26(6):695-702.
2. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2001 Jul, 25(1):1-27.
3. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biological Psychiatry 2001 Jan 1, 49(1):39-46.
4. Bustillo J.R., Rowland L.M., Jung R., Brooks W.M., Qualls C., Hammond R., et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2008 Sep, 33(10):2456-2466.
5. De Stefano N., Matthews P.M., Arnold D.L. Reversible decreases in N-acetylaspartate after acute brain injury. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 1995 Nov, 34(5):721-727.
6. Deicken R.F., Pegues M., Amend D. Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophrenia Research 1999 Jun 22, 37(3):217-223.
7. Exner C., Boucsein K., Degner D., Irle E., Weniger G. Impaired emotional learning and reduced amygdala size in schizophrenia: a 3-month follow-up. Schizophrenia Research 2004 Dec 1, 71(2-3):493-503.
8. Fannon D., Simmons A., Tennakoon L., O'Ceallaigh S., Sumich A., Doku V., et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biological Psychiatry 2003 Sep 15, 54(6):587-598.
9. Fujimoto T., Nakano T., Takano T., Takeuchi K., Yamada K., Fukuzako T., et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biological Psychiatry 1996 Jul 1, 40(1):14-18.
10. Grachev I.D., Ramachandran T.S., Thomas P.S., Szeverenyi N.M., Fredrickson B.E. Association between dorsolateral prefrontal N-acetyl aspartate and depression in chronic back pain: an in vivo proton magnetic resonance spectroscopy study. Journal of Neural Transmission 2003 Mar, 110(3):287-312. Vienna, Austria: 1996.
11. Harrison P.J. Neuropathology of schizophrenia. Psychiatry 2008, 7(10):421-424.
12. Harrison P.J. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 2004 Jun, 174(1):151-162.
13. Harte M.K., Bachus S.B., Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophrenia Research 2005 Jun 15, 75(2-3):303-308.
14. Harte M.K., Powell S.B., Reynolds L.M., Swerdlow N.R., Geyer M.A., Reynolds G.P. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. Biological Psychiatry 2004, 56(4):296-299.
15. Heimer L. The human brain and spinal cord 1983, Springer-Verlag, New York. 1st ed.
16. Hickie I., Naismith S., Ward P.B., Turner K., Scott E., Mitchell P., et al. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. The British Journal of Psychiatry: the Journal of Mental Science 2005 Mar, 186:197-202.
17. Jaarsma D., Veenma-van der Duin L., Korf J. N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. Journal of the Neurological Sciences 1994 Dec 20, 127(2):230-233.
18. Jessen F., Scherk H., Traber F., Theyson S., Berning J., Tepest R., et al. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophrenia Research 2006 Oct, 87(1-3):81-88.
19. Joyal C.C., Laakso M.P., Tiihonen J., Syvalahti E., Vilkman H., Laakso A., et al. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia. Biological Psychiatry 2002 Jun 15, 51(12):1005-1007.
20. Li B.S., Wang H., Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magnetic Resonance Imaging 2003 Oct, 21(8):923-928.
21. Maier M., Mellers J., Toone B., Trimble M., Ron M.A. Schizophrenia, temporal lobe epilepsy and psychosis: an in vivo magnetic resonance spectroscopy and imaging study of the hippocampus/amygdala complex. Psychological Medicine 2000 May, 30(3):571-581.
22. Michael N., Erfurth A., Ohrmann P., Arolt V., Heindel W., Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2003 Apr, 28(4):720-725.
23. Moffett J.R., Namboodiri M.A., Cangro C.B., Neale J.H. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991 Mar, 2(3):131-134.
24. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998 Aug 28, 281(5381):1349-1352. (New York, N.Y.).
25. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biological Psychiatry 2000 Jul 1, 48(1):1-8.
26. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends in Pharmacological Sciences 2005 Sep, 26(9):477-484.
27. Nudmamud S., Reynolds L.M., Reynolds G.P. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study. Biological Psychiatry 2003 Jun 15, 53(12):1138-1141.
28. Nudmamud-Thanoi S., Piyabhan P., Harte M.K., Cahir M., Reynolds G.P. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. Journal of Neural Transmission. Supplementum 2007, 72(72):281-285.
29. Ohrmann P., Kugel H., Bauer J., Siegmund A., Kolkebeck K., Suslow T., et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophrenia Research 2008 Dec, 106(2-3):156-163.
30. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995 Dec, 52(12):998-1007.
31. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biological Psychiatry 2008 Jan 1, 63(1):86-91.
32. Omori M., Pearce J., Komoroski R.A., Griffin W.S., Mrak R.E., Husain M.M., et al. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biological Psychiatry 1997 Sep 1, 42(5):359-366.
33. O'Neill J., Eberling J.L., Schuff N., Jagust W., Reed B., Soto G., et al. Method to correlate 1H MRSI and 18FDG-PET. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 2000 Feb, 43(2):244-250.
34. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Molecular and Chemical Neuropathology 1997 Jun, 31(2):97-118. sponsored by the International Society for Neurochemistry and the World Federation of Neurology and Research Groups on Neurochemistry and Cerebrospinal Fluid.
35. Petroff O.A., Errante L.D., Rothman D.L., Kim J.H., Spencer D.D. Neuronal and glial metabolite content of the epileptogenic human hippocampus. Annals of Neurology 2002 Nov, 52(5):635-642.
36. Prasad K.M., Rohm B.R., Keshavan M.S. Parahippocampal gyrus in first episode psychotic disorders: a structural magnetic resonance imaging study. Progress in Neuro-psychopharmacology and Biological Psychiatry 2004 Jul, 28(4):651-658.
37. Reynolds L.M., Cochran S.M., Morris B.J., Pratt J.A., Reynolds G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophrenia Research 2005 Mar 1, 73(2-3):147-152.
38. Sager T.N., Topp S., Torup L., Hanson L.G., Egestad B., Moller A. Evaluation of CA1 damage using single-voxel 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-asparate following global ischemia be used as a reliable measure of neuronal damage?. Brain Research 2001 Feb 16, 892(1):166-175.
39. Scherk H., Backens M., Schneider-Axmann T., Kemmer C., Usher J., Reith W., et al. Neurochemical pathology in hippocampus in euthymic patients with bipolar I disorder. Acta Psychiatrica Scandinavica 2008 Apr, 117(4):283-288.
40. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biological Psychiatry 1999 Jan 1, 45(1):17-25.
41. Sheline Y.I., Barch D.M., Donnelly J.M., Ollinger J.M., Snyder A.Z., Mintun M.A. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biological Psychiatry 2001 Nov 1, 50(9):651-658.
42. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proceedings of the National Academy of Sciences of the United States of America 1996 Apr 30, 93(9):3908-3913.
43. Sigmundsson T., Maier M., Toone B.K., Williams S.C., Simmons A., Greenwood K., et al. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophrenia Research 2003 Nov 1, 64(1):63-71.
44. Steen R.G., Hamer R.M., Lieberman J.A. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2005 Nov, 30(11):1949-1962.
45. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The Stanley foundation brain collection and neuropathology consortium. Schizophrenia Research 2000 Aug 3, 44(2):151-155.
46. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry 1995 Oct, 52(10):829-836.
47. Venkatraman T.N., Hamer R.M., Perkins D.O., Song A.W., Lieberman J.A., Steen R.G. Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus. NMR in Biomedicine 2006 Jun, 19(4):484-491.
48. Yamasue H., Fukui T., Fukuda R., Yamada H., Yamasaki S., Kuroki N., et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 2002 Nov 15, 13(16):2133-2137.
49. Yamasue H., Iwanami A., Hirayasu Y., Yamada H., Abe O., Kuroki N., et al. Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Research 2004 Sep 15, 131(3):195-207.
50. Yildiz-Yesiloglu A., Ankerst D.P. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progress in Neuro-psychopharmacology and Biological Psychiatry 2006 Aug 30, 30(6):969-995.
51. Zhang Z., Sun J., Reynolds G.P., Zhang Z. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chinese Medical Journal 2002, 115(6):819-823.